Delving into the Latest Updates on GL21.T with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

AXL

Mechanism

AXL inhibitors(AXL receptor tyrosine kinase inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Consiglio Nazionale delle Ricerche

Active Organization

Consiglio Nazionale delle Ricerche

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

AbstractCancer immunotherapy, which aims to eliminate cancer immunosuppression and reactivate anticancer immunity, holds great promise in oncology treatments. However, it is challenging to accurately study the efficacy of immunotherapy based on human‐derived cells through animal experiments due to xenogeneic immune rejection. Herein, a personalized and precise strategy to evaluate the effectiveness of immunotherapy using the blood samples of cancer patients is presented. Through the utilization of multiple cancer‐targeting delivery system decorated with the epidermal growth factor receptor (EGFR)‐specific aptamer CL4 and the AXL‐specific aptamer GL21.T to achieve superior efficiency in delivering the genome editing plasmid for MUC1 knockout, effective modulation on the behavior of circulating malignant cells (CMCs) is realized. After genome editing, both mucin 1 (MUC1) and programmed death‐ligand 1 (PD‐L1) are significantly downregulated in CMCs. The elimination of immunosuppression results in markedly enhanced secretion of pro‐inflammatory anticancer cytokines encompassing interleukins 2, 12, and 15 and interferon‐γ by immune cells. The study not only provides a strategy to overcome immunosuppression but also yields critical insights for personalized immunotherapy approaches.

100 Deals associated with GL21.T

Login to view more data